Still In The Race: Achillion Says Its HCV Candidates Are “Best-In-Class”
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
In a year of turmoil in HCV drug development, Achillion has advanced just by staying steady. The biotech’s plans are rooted in an NS5A inhibitor that shows efficacy in patients with mutated strains of the virus and a strong-performing protease inhibitor.